SCHEMBL23933185

SCHEMBL23933185

Cc1noc(C)c1-c1ccnc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 14/20 0.51
BRD2 P25440 5/20 0.51
CREBBP Q92793 4/20 0.49
FFAR1 O14842 1/20 0.46
BRD3 Q15059 1/20 0.46
ERN1 O75460 1/20 0.46
LMNA P02545 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
HIF1A Q16665 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
TSHR P16473 1/20 0.45
JAK2 O60674 1/20 0.44
USP2 O75604 1/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091007 0.80 PTGS2 (0.56)
SCHEMBL583542 0.80 BRD4 (0.51) BRD4BRD2CREBBPBRD3ERN1
SCHEMBL29135884 0.80 BRD4 (0.51) BRD4BRD2CREBBPBRD3ERN1
SCHEMBL12852647 0.78 CYP1A2 (0.60) BRD4BRD2CREBBPBRD3ERN1
SCHEMBL20888441 0.76 LMNA (0.48) BRD4BRD2CREBBPBRD3ERN1
SCHEMBL16404612 0.75 BRD4 (0.62) BRD4BRD2CREBBPBRD3LMNA
SCHEMBL13036077 0.75 BRD4 (0.56) BRD4BRD2CREBBPBRD3ERN1
SCHEMBL13036108 0.75 BRD4 (0.57) BRD4BRD2CREBBPBRD3ERN1
SCHEMBL30268696 0.74 BRD4 (0.68) BRD4BRD2CREBBPBRD3ERN1
SCHEMBL16404607 0.73 BRD4 (0.66) BRD4BRD2LMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202818-B2 Compounds and methods for CD73 modulation and indications therefor Opna Bio SA (CH) 2025-01-21 US disclosed
EP-4139296-B1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2024-09-18 EP disclosed
US-20240174640-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2024-05-30 US disclosed
US-11807626-B2 Compounds and methods for CD73 modulation and indications therefor Opna Bio SA (CH) 2023-11-07 US disclosed
CN-116323588-A Compounds and methods for CD73 modulation and indications therefor 奥普纳生物有限公司 2023-06-23 CN disclosed
EP-4139296-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Immuno Oncology, SA (CH) 2023-03-01 EP disclosed
US-20220144805-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2022-05-12 US disclosed
WO-2021216898-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202818-B2 Compounds and methods for CD73 modulation and indications therefor ENTPD5, ENTPD1, ADORA2A BRD4 3382/4885BRD2 4315/4885CREBBP 2341/4885
US-20240174640-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ENTPD1, ADORA2A BRD4 3382/4885BRD2 4315/4885CREBBP 2341/4885
US-11807626-B2 Compounds and methods for CD73 modulation and indications therefor ENTPD5, ENTPD1, ADORA2A BRD4 3382/4885BRD2 4315/4885CREBBP 2341/4885
US-20220144805-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ENTPD1, ADORA2A BRD4 3362/4885BRD2 4316/4885CREBBP 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.